Medical Technology

@xconomy.com 4 years ago

Podcast: How San Diego is Building a Biotech Ecosystem – Genomics & Precision Medicine Experts Weigh in

@xconomy.com 4 years ago

Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More

@xconomy.com 4 years ago

DTx Pharma Raises $10.6M to Advance New Way to Deliver RNA Drugs

@xconomy.com 4 years ago

Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More

@xconomy.com 4 years ago

Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone

@xconomy.com 4 years ago

New PCSK9 Cholesterol Drug Faces Tough Foe. (Hint: Not Cholesterol.)

@xconomy.com 4 years ago

California Life Sciences Fueled by Education, Established Companies

@xconomy.com 5 years ago

At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments

@xconomy.com 5 years ago

Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More

@xconomy.com 5 years ago

Biolinq Adds $4.75M to Advance Glucose Monitoring Biosensor Patch

@xconomy.com 5 years ago

Corza Health Emerges Led by Former NuVasive, GreatCall Executives

@xconomy.com 5 years ago

Connect Honors 7 New Products as ‘Most Innovative’ at Annual Awards

@xconomy.com 5 years ago

TP Therapeutics Names New CEO, Gets $80M More For Cancer Drug Push

@xconomy.com 5 years ago

Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More

@xconomy.com 5 years ago

With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?

@xconomy.com 5 years ago

IPO Wave Rolls On as Five Life Science Firms Haul in $651M

@xconomy.com 5 years ago

Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines

@xconomy.com 5 years ago

Will New Study Cut Guesswork for Depression Medicine Prescriptions?

@xconomy.com 6 years ago

Synthorx Raises $63M to Advance Suite of Enhanced Cytokine Drugs